BACKGROUND: @entity1897 is central to the pathogenesis of the accompanying @entity71 circulatory state and portal @entity101 in cirrhotic @entity1 . Selective intestinal decontamination with @entity4258 has been demonstrated to partially correct @entity842 production in the forearm vasculature of cirrhotic @entity1 . OBJECTIVE: To examine the effects of selective intestinal decontamination on regional and systemic hemodynamics in cirrhotic @entity1 . DESIGN: Randomized, double-blind, placebo-controlled, crossover study. SETTING: Alfred Hospital, Melbourne, Australia. @entity1 : 14 @entity1 with @entity167 -related @entity82 and 14 matched healthy controls. INTERVENTION: @entity4258 , 400 mg twice daily, for 4 weeks. MEASUREMENTS: @entity432 plethysmography was used to determine forearm blood flow. Cardiac output and the hepatic venous pressure gradient were determined after cardiac catheterization. Glomerular filtration rate was assessed by measuring inulin clearance. Serum levels of endotoxin were determined by chromogenic Limulus amebocytelysate assay. RESULTS: @entity4258 significantly diminished serum endotoxin levels (average change, -2.14 EU/mL [95% CI, -3.6 to -0.68 EU/mL]). Derived systemic vascular resistance increased significantly with @entity4258 (2.94 units [CI, 0.74 to 5.11 units]) and was accompanied by an increase in mean arterial pressure (8.70 mm Hg [CI, 2.65 to 14.73]), a trend toward decreased cardiac output (-1.207 L/min [range, 0.05 to -2.37 L/min]), a decrease in forearm blood flow (-0.99 mL/100 mL per min [CI, -1.80 to -0.17 mL/100 mL per min]), and a trend toward reduced hepatic venous pressure gradient (-2.43 mm Hg [CI, -5.2 to 0.34 mm Hg]). @entity4258 did not significantly alter glomerular filtration rate. CONCLUSION: Selective intestinal decontamination with @entity4258 partially reverses the hyperdynamic circulatory state in cirrhotic @entity1 without harming splanchnic or renal hemodynamics.

The effect of selective intestinal decontamination on the hyperdynamic circulatory state in XXXX . A randomized trial.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity4258 :: ('MESH:D009643', 'Chemical') :: ['Norfloxacin', 'norfloxacin'] @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol'] @entity71 :: ('MESH:D001289', 'Disease') :: ['hyperkinetic'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['Peripheral vasodilatation'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity432 :: ('MESH:D001157', 'Disease') :: ['Venous occlusion']
@entity82 :: (MESH:D005355,Disease) :: ['cirrhosis']
